Risk stratification scores for hospitalization duration and disease progression in moderate and severe patients with COVID-19

Table 4. The comparison of TRPNCLP with MuLBSTA score among severely ill COVID-19 patients

Models	AUC (95% CI)	P value	Cut-off value	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)	NRI (%) (95% CI)	P value	IDI (%) (95%CI)	P value
MuLBSTA	0.76 (0.73–0.79)	Ref	12	0.56 (0.43–0.68)	0.81 (0.77–0.84)	0.29 (0.23–0.35)	0.93 (0.91–0.95)	Ref	Ref	Ref	Ref
TRPNCLP	0.88 (0.85–0.91)	< 0.001	5	0.71 (0.59–0.82)	0.83 (0.80–0.87)	0.37 (0.32–0.43)	0.95 (0.93–0.97)	17.42 (4.31–30.53)	0.009	17.42 (4.21–30.62)	0.009

Bold indicates p < 0.05.
AUC, area under receiver operator characteristic (ROC) curve; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negetive predictive value; NRI, net reclassification improvement; IDI, integrated discrimination improvement; MuLBSTA, multilobular infiltration, hypo-lymphocytosis, bacterial coinfection, smoking history, hypertension and age; TRPNCLP, temperature, respiratory disease, platelet count, neutrophil-to-lymphocyte ratio, creatinine, lactate dehydrogenase, prothrombin time.

ISSN: 1471-2466